Cheap Aicar for sale, 100mg, 200mg, 500mg. Buy AICAR 500 mg online
|100 mg||USD 79||In-stock|
|200 mg||USD 130||In-stock|
|500 mg||USD 280||In-stock|
AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, 5-aminoimidazole-4-carboxamide ribonucleoside, acadesine) is each of several interesting things. First, it’s an important pharmacological research agent, used principally as an AMPK activator. It’s a compound which has shown extremely impressive fat-loss and endurance-enhancing effects in laboratory animals. Further, it has considerable mystique resulting from at least some use by elite European cyclists. And lastly, it’s readily available from research chemical sites and is being personally tried by many, though generally as part of stacks and combined with changes in training and/or diet. AICAR 500 mg
Aicar for sale
AICAR doses uses in research studies, results from treatment, and approximate human equivalent doses, assuming an about-200 lb (90 kg) human for illustration. AICAR 500 mg
AICAR (Acadesine) is an intermediate in the generation of inosine monophosphate. AICAR is an analog of adenosine monophosphate (AMP) that is capable of stimulating AMP-dependent protein kinase (AMPK) activity. AICAR has been used clinically to treat and protect against cardiac ischemic injury. The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery. The drug has also been shown as a potential treatment for diabetes by increasing the metabolic activity of tissues by changing the physical composition of muscle. Acadesine is an adenosine receptor agonist (ARA) in development for the treatment of ischaemia-reperfusion injury and chronic lymphocytic leukaemia. Schering-Plough is developing the compound as a cardioprotective agent in ischaemia-reperfusion injury. Avancell and Protherics are co-developing acadesine for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL). Clinical development is underway for both indications. AICAR, an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Orphan drug status has been granted for acadesine in the EU for the treatment of B-cell chronic lymphocytic leukaemia.